Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma
    Rognoni, Carla
    Ciani, Oriana
    Sommariva, Silvia
    Tarricone, Rosanna
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (03) : 209 - 221
  • [42] Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience
    Singla, Smit
    LeVea, Charles M.
    Pokuri, Venkata K.
    Attwood, Kristopher M.
    Wach, Michael M.
    Tomaszewski, Garin M.
    Kuvshinoff, Boris
    Iyer, Renuka
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (03) : 441 - 448
  • [43] A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant Recipients
    Agopian, Vatche G.
    Harlander-Locke, Michael
    Zarrinpar, Ali
    Kaldas, Fady M.
    Farmer, Douglas G.
    Yersiz, Hasan
    Finn, Richard S.
    Tong, Myron
    Hiatt, Jonathan R.
    Busuttil, Ronald W.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) : 416 - 427
  • [44] Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change
    Saberi, Behnam
    Gurakar, Ahmet
    Tamim, Hani
    Schneider, Carolin V.
    Sims, Omar T.
    Bonder, Alan
    Fricker, Zachary
    Alqahtani, Saleh A.
    JAMA NETWORK OPEN, 2023, 6 (11) : E2341096
  • [45] National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States
    Kwong, Allison J.
    Ghaziani, T. Tara
    Yao, Francis
    Sze, Daniel
    Mannalithara, Ajitha
    Mehta, Neil
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : 1142 - +
  • [46] Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C-Triggered Abbreviated MRI
    Mulgaonkar, Ashwini
    Huang, Daniel Q.
    Siddiqi, Harris
    Fowler, Kathryn
    Sirlin, Claude B.
    Marks, Robert
    Loomba, Rohit
    Konijeti, Gauree G.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (07) : 1326 - 1336
  • [47] Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter
    Ikeda, K
    Kobayashi, M
    Saitoh, S
    Someya, T
    Hosaka, T
    Sezaki, H
    Suzuki, Y
    Suzuki, F
    Akuta, N
    Arase, Y
    Kumada, H
    Matsuda, M
    Hashimoto, M
    Watanabe, G
    HEPATOLOGY RESEARCH, 2005, 33 (03) : 241 - 249
  • [48] Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Ramtohul, Toulsie
    Vilgrain, Valerie
    Soubrane, Olivier
    Bouattour, Mohamed
    Luciani, Alain
    Kobeiter, Hicham
    Mule, Sebastien
    Tacher, Vania
    Laurent, Alexis
    Amaddeo, Giuliana
    Regnault, Helene
    Bulsei, Julie
    Nault, Jean-Charles
    Nahon, Pierre
    Durand-Zaleski, Isabelle
    Seror, Olivier
    CANCERS, 2022, 14 (11)
  • [49] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Shuling Chen
    Zhenwei Peng
    Mengchao Wei
    Weifeng Liu
    Zihao Dai
    Haibo Wang
    Jie Mei
    Mingfong Cheong
    Hanmei Zhang
    Ming Kuang
    BMC Cancer, 18
  • [50] Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation
    Hu, Shuifang
    Wu, Xiaoxue
    Wei, Mengchao
    Ling, Yunyan
    Zhu, Meiyan
    Wang, Yan
    Chen, Yong
    Jin, Meng
    Peng, Zhenwei
    JOURNAL OF ONCOLOGY, 2022, 2022